Investor Presentaiton
Daiichi-Sankyo
ENHERTU
Performance in Each Region (US, EU)
Steady increase in product sales due to market penetration and additional indication
Global product sales: FY2022 Q1 results 31.3 Bn JPY (YOY +18.4 Bn JPY) FY2022 forecast 128.4 Bn JPY (YOY +63.0 Bn JPY)
US
Product sales: FY2022 Q1 results 20.0 Bn JPY (155 Mn USD)
FY2022 forecast 83.1 Bn JPY (639 Mn USD)
Indication: HER2+ BC 2L/3L, HER2+ GC 2L
Market share status
HER2+ BC 3L: Maintaining No.1 new patient share
HER2+ BC 2L: Achieving No.1 new patient share already
HER2+ GC 2L: Achieving No.1 new patient share
Other progress
➤ Approved for HER2+ BC 2L and started promotion (May 2022)
Classified as a category 1 preferred regimen for patients with tumors
that are HER2 IHC 1+ or 2+ and ISH negative in NCCN*1 guidelines
(Jun. 2022)
Europe
Product sales: FY2022 Q1 results 6.7 Bn JPY (52 Mn USD)
FY2022 forecast 23.0 Bn JPY (177 Mn USD)
Indication: HER2+ BC 2L/3L
Market share status
HER2+ BC 3L: Maintaining No.1 new patient share (UK, France,
Germany)
Other progress
Approved for HER2+ BC 2L and started promotion (Jul. 2022)
ENHERTU®
trastuzumab deruxtecan
*1 NCCN: National Comprehensive Cancer Network
12View entire presentation